Acadian Asset Management
MDGL icon

Acadian Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Acadian Asset Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08M Sell
2,013
-96
-5% -$49.2K ﹤0.01% 1243
2026
Q1 		$1.1M Sell
2,109
-1,849
-47% -$883K ﹤0.01% 1127
2025
Q4 		$2.3M Buy
+3,958
New +$2.02M ﹤0.01% 878
2024
Q4 		– Sell
-661
Closed -$140K – 1953
2024
Q3 		$140K Buy
+661
New +$169K ﹤0.01% 1486

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Acadian Asset Management's MDGL Position: Q2 2026 in Review

Acadian Asset Management reduced its Madrigal Pharmaceuticals (MDGL) stake by 4.6% in Q2 2026, selling an estimated $49.2K and leaving 2,013 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #1243.

Acadian Asset Management first reported a position in MDGL in Q3 2024 and has held it in 4 quarters since. The position peaked at $2.3M in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Acadian Asset Management held 2,013 shares of Madrigal Pharmaceuticals worth $1.08M as of Q2 2026.
  • Acadian Asset Management sold 96 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $49.2K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1243 holding.
  • Acadian Asset Management first reported a position in Madrigal Pharmaceuticals in Q3 2024 and has held it in 4 quarters since.
  • Acadian Asset Management's Madrigal Pharmaceuticals position peaked at $2.3M in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.